IN2012DN02046A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02046A IN2012DN02046A IN2046DEN2012A IN2012DN02046A IN 2012DN02046 A IN2012DN02046 A IN 2012DN02046A IN 2046DEN2012 A IN2046DEN2012 A IN 2046DEN2012A IN 2012DN02046 A IN2012DN02046 A IN 2012DN02046A
- Authority
- IN
- India
- Prior art keywords
- tvemps
- compositions
- mammal
- methods
- present specification
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23394709P | 2009-08-14 | 2009-08-14 | |
PCT/US2010/045659 WO2011020115A2 (en) | 2009-08-14 | 2010-08-16 | Methods of treating cancer using growth factor retargeted endopeptidases |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN02046A true IN2012DN02046A (en) | 2015-08-21 |
Family
ID=43478303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2046DEN2012 IN2012DN02046A (en) | 2009-08-14 | 2010-08-16 |
Country Status (9)
Country | Link |
---|---|
US (2) | US20110070186A1 (en) |
EP (1) | EP2464366A2 (en) |
KR (1) | KR20140015129A (en) |
CN (1) | CN102971001A (en) |
AU (1) | AU2010282274A1 (en) |
CA (1) | CA2771181A1 (en) |
IL (1) | IL218066A0 (en) |
IN (1) | IN2012DN02046A (en) |
WO (1) | WO2011020115A2 (en) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0820970D0 (en) | 2008-11-17 | 2008-12-24 | Syntaxin Ltd | Suppression of cancer |
US20100303757A1 (en) * | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases |
WO2013033680A1 (en) | 2011-09-02 | 2013-03-07 | Lifenet Health | Bmp peptides & methods of use |
US11078248B2 (en) | 2010-03-19 | 2021-08-03 | Lifenet Health | BMP peptides and methods of use |
EP2627350A1 (en) | 2010-10-14 | 2013-08-21 | Allergan, Inc. | Targeted delivery of targeted exocytosis modulators to the sphenopalatine ganglion for treatment of headache disorders |
WO2012112422A1 (en) * | 2011-02-14 | 2012-08-23 | Allergan, Inc. | Inhibiting aberrant blood vessel formation using growth factor retargeted endopeptidases |
US20120244188A1 (en) | 2011-03-25 | 2012-09-27 | Allergan, Inc. | Treatment of Sensory Disturbance Disorders |
US20120251574A1 (en) | 2011-03-28 | 2012-10-04 | Allergan, Inc. | Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions |
US20120251573A1 (en) | 2011-03-28 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Neuroendocrine Disorders |
US20120251575A1 (en) | 2011-03-28 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Involuntary Movement Disorders |
US20120251519A1 (en) | 2011-03-29 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Smooth Muscle Disorders |
US20120258132A1 (en) | 2011-03-29 | 2012-10-11 | Allergan, Inc. | Vagal Nerve-Based Disorders |
US20120251518A1 (en) | 2011-03-29 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Sexual Dysfunction Disorders |
US20120251515A1 (en) | 2011-03-29 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Cosmesis Disorders |
WO2012150254A1 (en) * | 2011-05-02 | 2012-11-08 | Baxter International Inc. | Fgf based fibrin binding peptides |
US9764009B2 (en) | 2011-06-13 | 2017-09-19 | Allergan, Inc. | Treatment of psychological trauma |
US20130171122A1 (en) | 2011-12-29 | 2013-07-04 | Allergan, Inc. | Endopeptidase and neurotoxin combination treatment of bladder disorders |
WO2014100019A1 (en) | 2012-12-18 | 2014-06-26 | Allergan, Inc. | Prophylactic treatment of herpes recurrence |
CN104634982B (en) * | 2013-11-06 | 2016-08-17 | 中国科学院上海生命科学研究院 | VEGF-C purposes in preparation septicemia and serious bacterial infections diagnostic reagent |
EP3194974B1 (en) * | 2014-09-16 | 2019-10-23 | Regeneron Pharmaceuticals, Inc. | Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer |
CA3015392A1 (en) | 2015-03-03 | 2016-09-09 | Wilfred Jefferies | Modulation of cancer immunity with type 2 innate lymphoid cells, interleukin 33, and/or interferon induced protein 44 |
CN108070651A (en) * | 2016-11-07 | 2018-05-25 | 苏州安康盟医疗科技有限公司 | A kind of diagnostic analysis/prognostic analysis method for assessing CRC risks of recurrence |
KR102277147B1 (en) * | 2017-12-13 | 2021-07-13 | 건국대학교 산학협력단 | Use of peptides derived from fibroblast growth factor to promote osteogenic or chondrogenic differentiation |
WO2018141313A2 (en) * | 2018-04-17 | 2018-08-09 | Novo Nordisk A/S | Uses of fgf-4 compounds |
GB201900621D0 (en) * | 2019-01-16 | 2019-03-06 | Ipsen Biopharm Ltd | Labelled polypeptides |
CN114075272B (en) * | 2020-08-10 | 2023-09-22 | 杭州俊丰生物工程有限公司 | Preparation method of human neuregulin 4 |
CN118146395A (en) * | 2021-02-08 | 2024-06-07 | 浙江大学 | Chimeric antigen receptor using endogenous protein molecules to replace single domain antibodies |
CN113621690B (en) * | 2021-07-26 | 2023-08-22 | 山西医科大学 | Application of interleukin 32 as target in screening and targeting medicine for treating esophageal squamous carcinoma |
CN114295839B (en) * | 2021-08-11 | 2024-06-07 | 首都医科大学附属北京地坛医院 | Application of HOXB7 protein in preparation of kit for identifying oligodendroglioma and astrocytoma |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6146886A (en) | 1994-08-19 | 2000-11-14 | Ribozyme Pharmaceuticals, Inc. | RNA polymerase III-based expression of therapeutic RNAs |
US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
US7740868B2 (en) | 1999-08-25 | 2010-06-22 | Allergan, Inc. | Activatable clostridial toxins |
US20080032931A1 (en) * | 1999-08-25 | 2008-02-07 | Steward Lance E | Activatable clostridial toxins |
US7838008B2 (en) * | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
US6726918B1 (en) | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
US6899717B2 (en) | 2002-09-18 | 2005-05-31 | Allergan, Inc. | Methods and apparatus for delivery of ocular implants |
US20040137059A1 (en) | 2003-01-09 | 2004-07-15 | Thierry Nivaggioli | Biodegradable ocular implant |
US20060182783A1 (en) | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
WO2006059093A2 (en) | 2004-12-01 | 2006-06-08 | Health Protection Agency | Fusion proteins |
EP1877073B1 (en) | 2004-12-01 | 2013-09-25 | The Secretary of State for Health | Non-cytotoxic protein conjugates |
EP2316847A3 (en) * | 2005-03-15 | 2012-01-18 | Allergan, Inc. | Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems |
US7993656B2 (en) * | 2006-07-11 | 2011-08-09 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
-
2010
- 2010-08-16 US US12/856,872 patent/US20110070186A1/en not_active Abandoned
- 2010-08-16 WO PCT/US2010/045659 patent/WO2011020115A2/en active Application Filing
- 2010-08-16 KR KR1020127006560A patent/KR20140015129A/en not_active Application Discontinuation
- 2010-08-16 CA CA2771181A patent/CA2771181A1/en not_active Abandoned
- 2010-08-16 IN IN2046DEN2012 patent/IN2012DN02046A/en unknown
- 2010-08-16 CN CN2010800456673A patent/CN102971001A/en active Pending
- 2010-08-16 EP EP10760807A patent/EP2464366A2/en not_active Withdrawn
- 2010-08-16 AU AU2010282274A patent/AU2010282274A1/en not_active Abandoned
-
2012
- 2012-02-12 IL IL218066A patent/IL218066A0/en unknown
- 2012-08-09 US US13/571,283 patent/US20130195838A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2464366A2 (en) | 2012-06-20 |
KR20140015129A (en) | 2014-02-06 |
US20130195838A1 (en) | 2013-08-01 |
IL218066A0 (en) | 2012-04-30 |
US20110070186A1 (en) | 2011-03-24 |
WO2011020115A2 (en) | 2011-02-17 |
CN102971001A (en) | 2013-03-13 |
CA2771181A1 (en) | 2011-02-17 |
AU2010282274A1 (en) | 2012-03-15 |
WO2011020115A3 (en) | 2013-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN02046A (en) | ||
WO2011020056A3 (en) | Methods of treating cancer using galanin retargeted endpeptidases | |
WO2011020114A3 (en) | Methods of treating cancer using tachykinin retargeted endopeptidases | |
WO2011020119A3 (en) | Methods of treating cancer using glucagon-like hormone retargeted endopeptidases | |
WO2011020117A3 (en) | Methods of treating cancer using neurotrophin retargeted endopeptidases | |
HK1216880A1 (en) | Certain triazolopyridines, compositions thereof and their use in the treatment of cancer. | |
MX344786B (en) | Compositions and methods for treating gaucher disease. | |
EP2569330A4 (en) | Chlorotoxin variants, conjugates, and methods for their use | |
HRP20160949T1 (en) | Novel compositions and methods for cancer treatment | |
IL218987A0 (en) | Methods and compositions for treating cancer | |
MX2010008817A (en) | Treatment of metastatic stage prostate cancer with degarelix. | |
ZA201203603B (en) | Lyophilization methods, compositions, and kits | |
PL2340042T3 (en) | Methods and compositions for the treatment of cancer | |
EP2419136A4 (en) | Compositions and methods for treating cancer | |
SG10201500124VA (en) | Methods and Compositions for Treating Cancer | |
EP2340027A4 (en) | Methods and compositions for the treatment of cancer | |
EP2381920A4 (en) | Methods and compositions for treating p.acnes | |
MY161601A (en) | Films and compositions comprising the same | |
IL219636A0 (en) | Methods and compositions for treating solid tumors and other malignancies | |
WO2011057220A9 (en) | Compositions and methods for treating lymphoma | |
EP2137213A4 (en) | Methods and compositions for treating prostate cancer | |
EP2597949A4 (en) | Sub-micron compositions | |
IL214757A0 (en) | Compositions and methods to prevent and/or treat cancer with pa-card | |
AU2010298020A8 (en) | Combination | |
SG178967A1 (en) | Antimicrobial compositions and products |